TCGA-62-8397-01A-11R-2326-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 70
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_912NX4Y0 | Ganglioglioma | — | 0.948 |
| 2 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.941 |
| 3 | SRR1381673 | GTEX | — | 0.939 |
| 4 | SRR1333352 | GTEX | — | 0.937 |
| 5 | SRR1488651 | GTEX | — | 0.936 |
| 6 | BS_0X9EGHY2 | low-grade glioma | — | 0.936 |
| 7 | SRR662091 | GTEX | — | 0.936 |
| 8 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.934 |
| 9 | MNG204 | — | — | 0.932 |
| 10 | SRR1472663 | GTEX | — | 0.932 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.410 | Remibrutinib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.030 | Idelalisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |